The “Bystander Effect”: Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified

Cancer Research

Volumn 53, Issue 21, 1993, Pages 5274-5283

  Freeman, Scott M ^a,a,b   Abboud, Camille ^a   Packman, Charles H ^a   Koeplin, David S ^c   Moolten, Frederick L ^d   Abraham, George N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL SCHOOL   (United States)

^b TULANE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

ARTICLE; CANCER SURVIVAL; CANCER THERAPY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSFER; GENETIC ANALYSIS; HERPES SIMPLEX VIRUS; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR MODEL; TUMOR REGRESSION;

ANIMAL; APOPTOSIS; CELL LINE, TRANSFORMED; FEMALE; GANCICLOVIR; KIRSTEN MURINE SARCOMA VIRUS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; RETROVIRIDAE INFECTIONS; SARCOMA, EXPERIMENTAL; SIMPLEXVIRUS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; THYMIDINE KINASE; TUMOR VIRUS INFECTIONS;

EID: 0027483695     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Itaya, T., Yamagiwa, S., Okada, F., Oikawa, T., Kuzumaki, N., Takeichi, N., Hosokawa, M. and Kobayashi, H. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Res., 47: 3136-3140, 1987.
2. Tepper, R. I., Pattengale, P. K. and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo., Cell, 57: 503-512, 1989.
3. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B. and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response., Cell, 60: 397-403, 1990.
4. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K. and Gilboa, E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res., 50: 7820-7825, 1990.
5. Gansbacher, B., Zier, K., Cronin, K., Hantzopoulos, P. A., Bouchard, B., Houghton, A., Gilboa, E. and Golde, D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood, 80: 2817-2825, 1992.
6. Larrick, J. W. and Burck, K. L. Treatment of human disease with gene therapy. In: Gene Therapy, Applications of Molecular Biology, pp. 77-104. New York: Elsevier Science Publishing Co. 1992.
7. Nishiyama, Y. and Rapp, F Anticellular effects of 9-(2-hydroxyethoxymethyl) guanine against herpes simplex virus transformed cells. J. Gen. Virol., 45: 227-235, 1979.
8. Elion, G. B. The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzyme Regul., 18: 53-66, 1980.
9. Oliver, S., Bubley, G. and Crumpacker, C. Inhibition of HSV-transformed murine cells by nucleoside analogs 2′-NDG and 2′-nor-GMP., Virology, 145: 84-93, 1985.
10. Garapin, F C. Chousterman, S., Horodniceanu, F., Kourilsky, P. and Garapin, X. C. Cloning of the active thymidine kinase gene of herpes simplex virus type 1 in E. coli k-12. Proc. Natl. Acad. Sci. USA, 76: 3755-3759, 1979.
11. Moolten, F Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
12. Borrelli, E., Heyman, R., Hsi, M. and Evans, R. M. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA, 85: 7572-7576, 1988.
13. Moolten, F., and J. M. Wells. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst., 82: 297-300, 1990.
14. Freeman, S. M., Whartenby, K. A., Koeplin, D. S., Moolten, F. L., Abboud, C. N. and Abraham, G. N. Tumor regression when a fraction of tumor mass contains the HSV-TK gene. J. Cell Biochem. 16F: 47, 1992.
15. Kolberg, R. Gene therapists test puzzling “bystander effect.” [News]. NIH Res. 4(No. 7): 68-74, 1992.
16. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608-614, 1991.
17. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H. and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.
18. Takamiya, Y., Short, M. P., Ezzeddine, Z. D., Moolten, F L., Breakefield, X. O. and Martuza, R. L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res., 33: 493-503, 1992.
19. Aaronson, S. A. and Weaver, C. A. Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J. Gen. Virol., 13: 245-252, 1971.
20. Miller, A. D. and Rossman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-990, 1989.
21. Bassin, R. H., Turtle, N., and Fischinger, P. J. Rapid cell culture assay technique for murine retroviruses. Nature (Lond.), 229: 564-566, 1971.
22. Crompton, T., Peitsch, M. C., MacDonald, H. R. and Tschopp, J. Propidium iodide staining correlates with the extent of DNA degradation in isolated nuclei. Biochem. Biophys. Res. Commun., 183: 532-537, 1992.
23. Slezak, S. E., and Horan, P. K. A highly sensitive and informative flow cytometric assay. J. Immunol. Methods, 117: 205-214, 1989.
24. Samlowski, W. E., Roberstson, B. A., Draper, B. K., Prystas, E., and McGregor, J. R. Effects of supravital fluorochromes used to analyze the in vivo homing of murine lymphocytes on cellular function. J. Immunol. Methods, 144: 101-115, 1991.
25. Lorber, M. I., Loken, M. R., Stall, A. M. and Fitch, F W. I-A antigens on cloned alloreactive murine T lymphocytes are acquired passively. J. Immunol., 128: 2798-2803, 1982.
26. Lockshin, R. A. and Zakeri, Z. Programmed cell death and apoptosis. Curr. Commun. Cell Mol. Biol., 3: 47-60, 1991.
27. Bowen, I. D. and Bowen, S. M. Cell death in tissues. In: I. D. Bowen and S. M. Bowen (eds.), Programmed Cell Death in Tumors and Tissues, pp. 15-29. London: Chapman and Hall, 1990.
28. Kerr, J. F. R. and Harmon, B. V. Definition and incidence of apoptosis: an historical perspective. Curr. Commun. Cell Mol. Biol., 3: 5-29, 1991.
29. Cooper, E. H., Bedford, A. J. and Kenny, T. E. Cell death in normal and malignant tissues. Adv. Cancer Res., 21: 59-120, 1975.
30. Rowden, G., Lewis, M. G. and Phillips, T. M. Cell deletion in primary and secondary human malignant melanomas. Pigm. Cell, 5: 257-265, 1979.
31. Cotter, T. G., Lennon, S. V., Glynn, J. G. and Martin, S. J. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells. Anticancer Res., 10: 1153-1160, 1990.
32. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L. and Henson, P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol., 148: 2207-2216, 1992.
33. Savill, J., Dransfield, I., Hogg, N., and Haslett, C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature (Lond.), 343: 170-173, 1990.
34. Duke, A. E., Smee, D. F., Chernow, M., Boehme, R., and Matthews, T. R. In vitro and in vivo activities of phosphate derivatives of 9-(l, 3-dihydroxy-2-propoxy methyl)-guanine against cytomegaloviruses. Antiviral Res., 6: 299-308, 1986.
35. Sommadossi, J. P. and Carlisle, R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(l, 3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother., 31: 452-454, 1987.
36. Faulds, D., and Heel, R. C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 39: 597-638, 1990.
37. Dagher, S. F., Conrad, S. E., Werner, E. A., and Patterson, R. J. Phenotypic conversion of TK-deficient cells following electroporation of functional TK enzyme. Exp. Cell Res., 198: 36-42, 1992.
38. Miller, F. R. McEachern D. and Miller, B. E. Efficiency of communication between tumor cells in collagen gel cultures. Br. J. Cancer, 62: 360-363, 1990.
39. Simpson, I., Rose, B., and Lowenstein, W. R. Size limit of molecules permeating the junctional membrane channels. Science (Washington DC), 195: 294-296, 1977.
40. Hogquist, K. A., Nett, M. A., Unanue, E. R. and Chaplin, D. D. Interleukin 1 is processed and released during apoptosis. Proc. Natl. Acad. Sci. USA, 88: 8485-8489, 1991.
41. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
42. Gastl, G., Finstad, C. L., Guarini, A., Bosl, G., Gilboa, E., Bander, N. H. and Gansbacher, B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res., 52: 6229-6236, 1992.
43. Moolten, F. L. and Cupples, L. A. A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther., 3: 479-486, 1992.
44. Ozols, R. F. Ovarian cancer, Part II: Treatment. Curr. Probl. Cancer, 16: 69-125, 1992.
45. Freeman, S. M., McCune, C., Angel, C., Abraham, G. N. and Abboud, C. N. Treatment of ovarian cancer using HSV-TK gene modified vaccine—regulatory issues. Hum. Gene Ther., 3: 342-349, 1992.